Czarnogorski M, Benn P, McCoig C, Nwafor T, et al. Brief Report: Impact of COVID-19 on Cabotegravir Plus Rilpivirine Long-Acting Dosing Across 6 Ongoing Global Phase IIb and III Clinical Trials. J Acquir Immune Defic Syndr 2022;91:157-161.
PMID: 36094481